Skip to main content

Table 1 Main patient characteristics

From: NKX2–1 expression as a prognostic marker in early-stage non-small-cell lung cancer

Characteristics Value N = 110 OS NKX2–1
N (%) p-value p-value
Sex Male 87 (79.1) 0.019 0.196
Female 23 (20.9)   
Age, yrs Mean (Range) 66.1 (32–84) 0.018 0.181
<=65 51 (46.4)   
>65 59 (53.6)   
ECOG PS 0 20 (18.2) 0.067 0.109
1 90 (81.8)   
Stage I 81 (73.6) 0.334 0.429
II 29 (26.4)   
Histology ADK 57 (51.8) 0.325 p < 0.001
SCC 44 (40)   
Large-cell Carcinoma 5 (4.5)   
Lepidic ADK 2 (1.8)   
Mixed adenosquamous 2 (1.8)   
Type of surgery Lobectomy/Bilobectomy 94 (85.5) 0.973
Pneumonectomy 5 (8.1)   
Atypical Resection 7 (6.4)   
Smoking history Current Smoker 40 (36.3) 0.075 0.025
Former Smoker 58 (52.7)   
Never smoker 12 (10.9)   
Adjuvant treatment Yes 26 (23.6) 0.663
No 84 (76.4)   
Relapse No 76 (69.1) 0.794
Yes 34 (30.9)   
Emphysema Yes 54 (49.1) 0.223 0.389
No 49 (44.5)   
Unknown 7 (6.4)   
COPD Yes 71 (64.5) 0.574 0.127
No 39 (35.5)   
DLCO (%) Mean (Range) 73 (35–100)
Molecular Features TP53 mutation 33/104 (30) 0.680 0.001
KRAS mutation 21/109 (19.1) 0.815 0.204
EGFRa 14/58 (24.1) 0.109 0.696
  1. OS overall survival, ECOG PS Eastern Cooperative Oncology Group performance status, ADK adenocarcinoma, SCC squamous cell carcinoma, COPD chronic obstructive pulmonary disease, DLCO diffusing capacity of the lung for carbon monoxide
  2. aEGFR mutational status was assessed only in adenocarcinoma patients